In March 2016, letters were sent regarding SGLT2 inhibitors, insulin lispro, natalizumab, noradrenaline, radium-223 dichloride, aflibercept and idelalisib.
In March 2016, letters were sent to healthcare professionals regarding:
- .SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis during treatment (see also the article in this issue)
- insulin lispro (Humalog 200 units/mL KwikPen): correct use to minimise medication errors
- natalizumab (Tysabri▼): updates to PML risk minimisation measures (see also the article in this issue)
- noradrenaline (norepinephrine) 0.08 mg/mL (4 mg in 50 mL) solution for infusion in a vial: potential risk of medication errors
- radium-223 dichloride (Xofigo▼): change in NIST standard reference material – information on implementation
- aflibercept (Zaltrap▼): information on the risk of osteonecrosis of the jaw (see also the article in this issue)
- idelalisib (Zydelig▼): restrictions in use for the treatment of chronic lymphocytic leukaemia and relapsed follicular lymphoma following new clinical trial results
Article citation: Drug Safety Update volume 9 issue 9, April 2016: 10.